Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 1,706,804	$ 1,980,015
Accounts receivable	2,248
Inventory		22,666
Advance to related party		58,135
Prepaid expense and other current assets	10,328	23,635
Total current assets	1,719,380	2,084,451
Patents, net	178,257	182,386
Property and equipment, net	22,693	26,997
Total assets	1,920,330	2,293,834
Liabilities and Stockholders' Deficit
Accounts payable and accrued expenses	139,492	159,300
Advances from investors	301,773	777,258
Customer deposits	7,491
Convertible notes payable – related party	691,481	886,481
Total current liabilities	1,140,237	1,823,039
Total liabilities	1,140,237	1,823,039
Commitments and contingencies
Stockholders' equity (deficit)
Preferred stock, $0.01 par value: Authorized shares - 10,000,000, Issued and outstanding shares – 0 at March 31, 2018 and December 31, 2017
Common stock, $0.01 par value: Authorized shares - 100,000,000, Issued and outstanding shares –33,724,261 and 23,156,563 at March 31, 2018 and December 31, 2017, respectively	337,243	231,565
Additional paid-in capital	2,514,263	2,123,205
Accumulated deficit	(2,152,579)	(1,883,975)
Total Amarillo Bioscience’s Inc. equity (deficit)	698,927	470,795
Non-controlling interests	81,166
Total stockholders’ equity (deficit)	780,093	470,795
Total liabilities and stockholders’ equity (deficit)	$ 1,920,330	$ 2,293,834